文献速递乳腺癌

乳腺癌易感基因致病变异携带者的乳腺癌风险随多基因风险评分变化

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
PubMed 文献 · J Clin Oncol · 2021-06-08

结果显示,结合多基因风险评分后,超过95%的BRCA1、BRCA2和PALB2携带者终生风险>20%,而部分ATM和CHEK2携带者可低于20%阈值。将多基因风险评分纳入风险评估有助于避免过度筛查并实现更个性化的风险管理。

要点

  • 多基因风险评分可细化易感基因致病变异携带者的乳腺癌终生风险分层。
  • 超过95%的BRCA1、BRCA2和PALB2携带者终生风险>20%。
  • 结合多基因风险评分可识别部分ATM和CHEK2携带者终生风险低于20%。

核心结论

  • 多基因风险评分有助于在乳腺癌易感基因致病变异携带者中实现乳腺癌风险的个性化评估。

研究设计与样本

  • 纳入26,798例非西班牙裔白人乳腺癌病例和26,127例对照,来自以人群为基础的癌症易感性风险估计联盟研究。
  • 评估BRCA1、BRCA2、ATM、CHEK2、PALB2、BARD1、BRIP1、CDH1和NF1的致病变异。
  • 基于105个常见变异构建总体及雌激素受体特异性多基因风险评分,采用惩罚逻辑回归估计比值比,并结合年龄别发病率估算5年和终生绝对风险。

主要发现

  • 在无致病变异的一般人群中,根据多基因风险评分第10至90百分位,有或无一级亲属乳腺癌家族史者的终生风险分别为9.1%-23.9%和6.7%-18.2%。
  • 考虑多基因风险评分后,超过95%的BRCA1、BRCA2和PALB2携带者终生风险>20%。
  • 无一级亲属乳腺癌家族史的ATM和CHEK2携带者中,分别有52.5%和69.7%终生风险>20%;有家族史者中分别为78.8%和89.9%。

临床怎么用

  • 将多基因风险评分纳入乳腺癌风险估算,可能帮助识别超过30%的CHEK2携带者和近半数ATM携带者终生风险低于20%阈值。
  • 上述结果提示加入多基因风险评分可能避免过度筛查并实现更个性化的风险管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study assessed the joint association of pathogenic variants (PVs) in breast cancer (BC) predisposition genes and polygenic risk scores (PRS) with BC in the general population. METHODS: A total of 26,798 non-Hispanic white BC cases and 26,127 controls from predominately population-based studies in the Cancer Risk Estimates Related to Susceptibility consortium were evaluated for PVs in BRCA1, BRCA2, ATM, CHEK2, PALB2, BARD1, BRIP1, CDH1, and NF1. PRS based on 105 common variants were created using effect estimates from BC genome-wide association studies; the performance of an overall BC PRS and estrogen receptor-specific PRS were evaluated. The odds of BC based on the PVs and PRS were estimated using penalized logistic regression. The results were combined with age-specific incidence rates to estimate 5-year and lifetime absolute risks of BC across percentiles of PRS by PV status and first-degree family history of BC. RESULTS: The estimated lifetime risks of BC among general-population noncarriers, based on 10th and 90th percentiles of PRS, were 9.1%-23.9% and 6.7%-18.2% for women with or without first-degree relatives with BC, respectively. Taking PRS into account, more than 95% of BRCA1, BRCA2, and PALB2 carriers had > 20% lifetime risks of BC, whereas, respectively, 52.5% and 69.7% of ATM and CHEK2 carriers without first-degree relatives with BC, and 78.8% and 89.9% of those with a first-degree relative with BC had > 20% risk. CONCLUSION: PRS facilitates personalization of BC risk among carriers of PVs in predisposition genes. Incorporating PRS into BC risk estimation may help identify > 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent overscreening and enable more personalized risk management approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gao C, Polley EC, Hart SN, et al. Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. J Clin Oncol. 2021. PMID: 34101481. doi:10.1200/JCO.20.01992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。